Mount Sinai Dermatologist Reports Phase 3 Success for Rocatinlimab in Moderate-to-Severe Eczema
November 26, 2025
November 26, 2025
NEW YORK, Nov. 26 (TNSjou) -- The Ichan School of Medicine at Mount Sinai posted the following news release:
* * *
Mount Sinai Dermatologist Reports Phase 3 Success for Rocatinlimab in Moderate-to-Severe Eczema
Two global trials show durable improvements in skin clearance, itch, and quality of life by targeting OX40 immune receptor
*
An international team of investigators led by Emma Guttman-Yassky, MD, PhD, Waldman Professor and S . . .
* * *
Mount Sinai Dermatologist Reports Phase 3 Success for Rocatinlimab in Moderate-to-Severe Eczema
Two global trials show durable improvements in skin clearance, itch, and quality of life by targeting OX40 immune receptor
*
An international team of investigators led by Emma Guttman-Yassky, MD, PhD, Waldman Professor and S . . .